Posted by Michael Wonder on 25 Nov 2016
EMA publishes EPAR for Ibrance
25 November 2016 - The EMA has published an EPAR for Pfizer's new cyclin-dependent kinase (CDK4/6) inhibitor.
Ibrance was approved by the European Commission on 9 November 2016 for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer:
- in combination with an aromatase inhibitor
- in combination with fulvestrant in women who have received prior endocrine therapy
Ibrance will be subjected to additional monitoring by the EMA.
